427 related articles for article (PubMed ID: 24332948)
21. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
[TBL] [Abstract][Full Text] [Related]
22. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Zhang Z; Ma J; Li N; Sun N; Wang C
Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
[TBL] [Abstract][Full Text] [Related]
23. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.
Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Pontén F; König A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenführer J; Hengstler JG; Micke P
Clin Cancer Res; 2013 Jan; 19(1):194-204. PubMed ID: 23032747
[TBL] [Abstract][Full Text] [Related]
24. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
25. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
[TBL] [Abstract][Full Text] [Related]
26. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures.
Fan J; Wang L; Jiang GN; He WX; Ding JA
Lung Cancer; 2008 Jul; 61(1):91-6. PubMed ID: 18192073
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer.
Wang ZX; Bian HB; Wang JR; Cheng ZX; Wang KM; De W
J Surg Oncol; 2011 Dec; 104(7):847-51. PubMed ID: 21721011
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
Zhao S; Qiu Z; He J; Li L; Li W
Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
31. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
[TBL] [Abstract][Full Text] [Related]
32. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
[TBL] [Abstract][Full Text] [Related]
33. Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status.
Ou SH; Zell JA; Ziogas A; Anton-Culver H
Cancer; 2008 May; 112(9):2011-20. PubMed ID: 18361399
[TBL] [Abstract][Full Text] [Related]
34. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
35. Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies.
Yu Y; Zhao Q; Wang Z; Liu XY
Cancer Chemother Pharmacol; 2015 May; 75(5):917-22. PubMed ID: 25735252
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis.
Deng XF; Liu QX; Zhou D; Min JX; Dai JG
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):21-7. PubMed ID: 25883247
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.
Russell K; Healy B; Pantarotto J; Laurie SA; MacRae R; Sabri E; Wheatley-Price P
Clin Lung Cancer; 2014 May; 15(3):237-43. PubMed ID: 24461300
[TBL] [Abstract][Full Text] [Related]
38. The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients.
Li X; Yu Z; Li Y; Liu S; Gao C; Hou X; Yao R; Cui L
Int J Oncol; 2015 Feb; 46(2):798-808. PubMed ID: 25531908
[TBL] [Abstract][Full Text] [Related]
39. The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.
Chen Z; Wang J; Bai Y; Wang S; Yin X; Xiang J; Li X; He M; Zhang X; Wu T; Xu P; Guo H
Cancer Gene Ther; 2017 Jan; 24(1):20-27. PubMed ID: 27982019
[TBL] [Abstract][Full Text] [Related]
40. VEGF-C in non-small cell lung cancer: meta-analysis.
Jiang H; Shao W; Zhao W
Clin Chim Acta; 2014 Jan; 427():94-9. PubMed ID: 24144865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
